Prevalence and risk factors of cancer-related fatigue: a systematic review and meta-analysis
Y Ma, B He, M Jiang, Y Yang, C Wang, C Huang… - International Journal of …, 2020 - Elsevier
Background Cancer-related fatigue, one of the most frequent side-effects of cancer
treatment, affects the well-being of patients. Despite the fact that the estimated prevalence …
treatment, affects the well-being of patients. Despite the fact that the estimated prevalence …
[HTML][HTML] Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score≥ 2–systematic review and meta-analysis
Abstract Background Immune checkpoint inhibitors (ICIs) are standard of care in advanced
non-small cell lung cancer (NSCLC), however their status in patients with poor performance …
non-small cell lung cancer (NSCLC), however their status in patients with poor performance …
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing …
SM Lee, C Schulz, K Prabhash, D Kowalski… - The Lancet, 2023 - thelancet.com
Background Despite immunotherapy advancements for patients with advanced or metastatic
non-small-cell lung cancer (NSCLC), pivotal first-line trials were limited to patients with an …
non-small-cell lung cancer (NSCLC), pivotal first-line trials were limited to patients with an …
[HTML][HTML] COVID-19 interstitial pneumonia: monitoring the clinical course in survivors
G Raghu, KC Wilson - The Lancet Respiratory Medicine, 2020 - thelancet.com
COVID-19 is an acute respiratory disease caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). Since the first case was identified, 1 the rapid emergence of …
coronavirus 2 (SARS-CoV-2). Since the first case was identified, 1 the rapid emergence of …
Association of performance status with survival in patients with advanced non–small cell lung cancer treated with pembrolizumab monotherapy
Importance Despite approximately 40% of patients having Eastern Cooperative Oncology
Group (ECOG) performance status (PS) scores of at least 2 in the real world, most landmark …
Group (ECOG) performance status (PS) scores of at least 2 in the real world, most landmark …
[HTML][HTML] Short-term preoperative high-intensity interval training in patients awaiting lung cancer surgery: a randomized controlled trial
Introduction Impairment in aerobic fitness is a potential modifiable risk factor for
postoperative complications. In this randomized controlled trial, we hypothesized that a high …
postoperative complications. In this randomized controlled trial, we hypothesized that a high …
[HTML][HTML] Safety, efficacy, and patient-reported health-related quality of life and symptom burden with nivolumab in patients with advanced non–small cell lung cancer …
DR Spigel, M McCleod, RM Jotte, L Einhorn… - Journal of Thoracic …, 2019 - Elsevier
Abstract Introduction CheckMate 153 (NCT02066636) is a phase 3B/4 study assessing
nivolumab in previously treated patients with advanced NSCLC. Eligibility criteria allowed …
nivolumab in previously treated patients with advanced NSCLC. Eligibility criteria allowed …
[HTML][HTML] Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of …
T Kawaguchi, M Takada, A Kubo, A Matsumura… - Journal of Thoracic …, 2010 - Elsevier
Background Performance status (PS) is an important factor in determining survival outcome
in non-small cell lung cancer (NSCLC) but is generally confounded by stage, age, gender …
in non-small cell lung cancer (NSCLC) but is generally confounded by stage, age, gender …
Relationship between deficits in overall quality of life and non–small-cell lung cancer survival
JA Sloan, X Zhao, PJ Novotny, J Wampfler… - Journal of clinical …, 2012 - ascopubs.org
Purpose Evidence has suggested a clinically meaningful relationship between self-reported
quality of life (QOL) of a patient with cancer at the time of receiving a cancer diagnosis and …
quality of life (QOL) of a patient with cancer at the time of receiving a cancer diagnosis and …
American College of Chest Physicians and Society of Thoracic Surgeons consensus statement for evaluation and management for high-risk patients with stage I non …
J Donington, M Ferguson, P Mazzone, J Handy Jr… - Chest, 2012 - Elsevier
Background The standard treatment of stage I non-small cell lung cancer (NSCLC) is
lobectomy with systematic mediastinal lymph node evaluation. Unfortunately, up to 25% of …
lobectomy with systematic mediastinal lymph node evaluation. Unfortunately, up to 25% of …